Opened with an aim to capitalize early-stage opportunities in healthcare segment, Johnson & Johnson Innovation center represents the third of four regional hubs being set up across the world as part of the Johnson & Johnson Innovation program.
Housing a group of business, science and transaction specialists, the center will concentrate on recognizing and building novel early-stage collaborations with rising companies, entrepreneurs and academic centers throughout eastern North America.
Commenting on the launch of the new centre, Johnson & Johnson managing director, chief scientific officer and worldwide chairman, pharmaceuticals Paul Stoffels said that the new center is one step ahead to partner with some eminent scientists, academic centers and influential entrepreneurs.
In order to identify and invest in external opportunities, Johnson & Johnson venture capital subsidiary’s Johnson & Johnson Development Corporation (JJDC) representatives have been co-located at the Boston Innovation Center.
With the opening of the centre, Johnson & Johnson has established a research partnership with Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease (IBD) and the discovery of next generation therapeutic solutions.
Additionally, the Boston Innovation Center and Janssen Research & Development, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, will engage in scientific collaboration with Rodin Therapeutics.
JJDC has also invested in Vedanta Biosciences for its collaboration with the Boston Innovation Center.